ES2952748T3 - Muestra de tejido periférico que contiene células que expresan el 5HTR2C y/o las ADAR como marcadores de la alteración del mecanismo de edición del ARNm de 5HTR2C y sus aplicaciones - Google Patents
Muestra de tejido periférico que contiene células que expresan el 5HTR2C y/o las ADAR como marcadores de la alteración del mecanismo de edición del ARNm de 5HTR2C y sus aplicaciones Download PDFInfo
- Publication number
- ES2952748T3 ES2952748T3 ES17185202T ES17185202T ES2952748T3 ES 2952748 T3 ES2952748 T3 ES 2952748T3 ES 17185202 T ES17185202 T ES 17185202T ES 17185202 T ES17185202 T ES 17185202T ES 2952748 T3 ES2952748 T3 ES 2952748T3
- Authority
- ES
- Spain
- Prior art keywords
- adar
- mrna
- editing
- 5htr2c
- expression products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 title claims abstract description 93
- 101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 title claims abstract description 92
- 230000017156 mRNA modification Effects 0.000 title claims abstract description 45
- 230000004075 alteration Effects 0.000 title claims abstract description 36
- 230000002093 peripheral effect Effects 0.000 title claims abstract description 31
- 230000007246 mechanism Effects 0.000 title claims abstract description 27
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 title claims description 101
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 title claims description 96
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 109
- 238000000034 method Methods 0.000 claims abstract description 72
- 210000004369 blood Anatomy 0.000 claims abstract description 49
- 239000008280 blood Substances 0.000 claims abstract description 49
- 230000007170 pathology Effects 0.000 claims abstract description 32
- 230000003321 amplification Effects 0.000 claims abstract description 23
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 23
- 238000000338 in vitro Methods 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 230000001419 dependent effect Effects 0.000 claims abstract description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 8
- 238000001727 in vivo Methods 0.000 claims abstract description 5
- 230000014509 gene expression Effects 0.000 claims description 85
- 108010029485 Protein Isoforms Proteins 0.000 claims description 70
- 102000001708 Protein Isoforms Human genes 0.000 claims description 70
- 210000004027 cell Anatomy 0.000 claims description 64
- 239000000523 sample Substances 0.000 claims description 61
- 101000742223 Homo sapiens Double-stranded RNA-specific editase 1 Proteins 0.000 claims description 42
- 210000004556 brain Anatomy 0.000 claims description 41
- 241000282414 Homo sapiens Species 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 29
- 108090000623 proteins and genes Proteins 0.000 claims description 28
- 102100038191 Double-stranded RNA-specific editase 1 Human genes 0.000 claims description 24
- 239000012472 biological sample Substances 0.000 claims description 24
- 210000000601 blood cell Anatomy 0.000 claims description 21
- 241000124008 Mammalia Species 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 17
- 230000002441 reversible effect Effects 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 230000009543 pathological alteration Effects 0.000 claims description 10
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 108020004635 Complementary DNA Proteins 0.000 claims description 6
- 206010010144 Completed suicide Diseases 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 238000010839 reverse transcription Methods 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 102000043770 human ADAR Human genes 0.000 claims description 4
- 208000020016 psychiatric disease Diseases 0.000 claims description 4
- 206010065604 Suicidal behaviour Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 108700007502 mouse ADAR1 Proteins 0.000 claims description 3
- 108700007949 mouse ADAR2 Proteins 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 101100468236 Mus musculus Adarb1 gene Proteins 0.000 claims description 2
- 230000020595 eating behavior Effects 0.000 claims description 2
- 102000044898 human ADARB1 Human genes 0.000 claims description 2
- 238000001742 protein purification Methods 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- 101100388222 Mus musculus Adar gene Proteins 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 abstract description 15
- 238000007857 nested PCR Methods 0.000 abstract description 8
- 239000012634 fragment Substances 0.000 abstract description 7
- 102000055025 Adenosine deaminases Human genes 0.000 abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 abstract description 5
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 abstract description 3
- 108700040115 Adenosine deaminases Proteins 0.000 abstract description 3
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- 238000013519 translation Methods 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 48
- 210000003491 skin Anatomy 0.000 description 41
- 210000001519 tissue Anatomy 0.000 description 41
- 238000010357 RNA editing Methods 0.000 description 18
- 230000026279 RNA modification Effects 0.000 description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 239000003550 marker Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 13
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 12
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine group Chemical group [C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 229930010555 Inosine Natural products 0.000 description 7
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 7
- 230000000875 corresponding effect Effects 0.000 description 7
- 229960003786 inosine Drugs 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 210000002442 prefrontal cortex Anatomy 0.000 description 7
- 230000000862 serotonergic effect Effects 0.000 description 7
- 108010047761 Interferon-alpha Proteins 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 229940076279 serotonin Drugs 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000005251 capillar electrophoresis Methods 0.000 description 5
- 230000000994 depressogenic effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 210000004927 skin cell Anatomy 0.000 description 5
- 238000010200 validation analysis Methods 0.000 description 5
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 4
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 238000011888 autopsy Methods 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 101150112014 Gapdh gene Proteins 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100024228 High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A Human genes 0.000 description 3
- 101001117261 Homo sapiens High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A Proteins 0.000 description 3
- 108010044467 Isoenzymes Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 230000009615 deamination Effects 0.000 description 3
- 238000006481 deamination reaction Methods 0.000 description 3
- 230000003831 deregulation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 210000004326 gyrus cinguli Anatomy 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 230000007310 pathophysiology Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- 101100296682 Arabidopsis thaliana PCR10 gene Proteins 0.000 description 2
- 101100519165 Arabidopsis thaliana PCR9 gene Proteins 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101150102573 PCR1 gene Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 101150081775 adaR gene Proteins 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000036651 mood Effects 0.000 description 2
- 230000008726 multistep metabolic pathway Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002360 prefrontal effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VOUZLOAKKHFAOZ-UHFFFAOYSA-N 3-(5-methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid Chemical compound CC=1ON=C(O)C=1CCC(O)=O VOUZLOAKKHFAOZ-UHFFFAOYSA-N 0.000 description 1
- 229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 1
- 102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 1
- 101710138092 5-hydroxytryptamine receptor 2B Proteins 0.000 description 1
- 101150102859 ADARB2 gene Proteins 0.000 description 1
- 108010005456 AMPA 4 glutamate receptor ionotropic Proteins 0.000 description 1
- 108090000078 AMPA Receptors Proteins 0.000 description 1
- 102000003678 AMPA Receptors Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 101100519160 Arabidopsis thaliana PCR4 gene Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 206010012397 Depression suicidal Diseases 0.000 description 1
- 102100024692 Double-stranded RNA-specific editase B2 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 102100030668 Glutamate receptor 4 Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000686486 Homo sapiens Double-stranded RNA-specific editase B2 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000799160 Homo sapiens tRNA-specific adenosine deaminase 1 Proteins 0.000 description 1
- 101150013372 Htr2c gene Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- MVAWJSIDNICKHF-UHFFFAOYSA-N N-acetylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CNC2=C1 MVAWJSIDNICKHF-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 230000021839 RNA stabilization Effects 0.000 description 1
- 101100356267 Rattus norvegicus Adarb1 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229920006328 Styrofoam Polymers 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 201000008257 amyotrophic lateral sclerosis type 1 Diseases 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000010221 calcium permeability Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000009850 completed effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229950000038 interferon alfa Drugs 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 108700029353 mouse Ifna Proteins 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102200065564 rs6318 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002484 serotonin 2C antagonist Substances 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000019929 sporadic amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008261 styrofoam Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 102100034113 tRNA-specific adenosine deaminase 1 Human genes 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 238000012418 validation experiment Methods 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94368507P | 2007-06-13 | 2007-06-13 | |
| US2323908P | 2008-01-24 | 2008-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2952748T3 true ES2952748T3 (es) | 2023-11-03 |
Family
ID=39776384
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17185202T Active ES2952748T3 (es) | 2007-06-13 | 2008-06-13 | Muestra de tejido periférico que contiene células que expresan el 5HTR2C y/o las ADAR como marcadores de la alteración del mecanismo de edición del ARNm de 5HTR2C y sus aplicaciones |
| ES08761038.2T Active ES2646592T3 (es) | 2007-06-13 | 2008-06-13 | Muestra de tejido periférico que contiene células que expresan 5HTR2C y/o ADARs, como marcadores de la alteración del mecanismo de edición del ARNm de 5HTR2C y sus aplicaciones |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08761038.2T Active ES2646592T3 (es) | 2007-06-13 | 2008-06-13 | Muestra de tejido periférico que contiene células que expresan 5HTR2C y/o ADARs, como marcadores de la alteración del mecanismo de edición del ARNm de 5HTR2C y sus aplicaciones |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP2162550B1 (enExample) |
| JP (1) | JP5661458B2 (enExample) |
| CN (1) | CN101743322B (enExample) |
| CA (1) | CA2690909C (enExample) |
| ES (2) | ES2952748T3 (enExample) |
| WO (1) | WO2008152146A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2202321A1 (en) | 2008-12-17 | 2010-06-30 | Biocortech | Evaluation of the potential risk of drug induced mood disturbance and suicide:use of a dedicated platform |
| US11873531B2 (en) * | 2010-06-24 | 2024-01-16 | Alcediag | Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects |
| WO2011161253A1 (en) * | 2010-06-24 | 2011-12-29 | Biocortech | Editing profiling of pde8a pre -mrna : use as specific biomarker of adars activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects |
| CN102146119A (zh) * | 2011-01-17 | 2011-08-10 | 山东大学齐鲁医院 | 一种小鼠表皮总蛋白的提取方法 |
| JP7227006B2 (ja) * | 2016-03-11 | 2023-02-21 | アルスディアグ | 活性化合物によって誘発される特定の効果を選択するための、ｒｎａ編集に基づくアルゴリズム及びインビトロの方法 |
| US12084719B2 (en) * | 2016-07-28 | 2024-09-10 | Alcediag | RNA editing as biomarkers for mood disorders test |
| CN110352244B (zh) * | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| EP3819387A1 (en) * | 2019-11-08 | 2021-05-12 | Alcediag | Differential diagnosis of bipolar disorder and unipolar depression by blood rna editing biomarkers |
| EP3819386A1 (en) * | 2019-11-08 | 2021-05-12 | Alcediag | Diagnosing of mood disorders using blood rna editing biomarkers |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763174A (en) * | 1994-02-17 | 1998-06-09 | The Wistar Institute Of Anatomy & Biology | RNA editing enzyme and methods of use thereof |
| FR2842827B1 (fr) * | 2002-07-26 | 2004-10-22 | Biocortech | NOUVELLE METHODE D'ANALYSE D'ACIDE NUCLEIQUE ET SON UTILISATION POUR EVALUER LE DEGRE D'EDITION DE L'ARNm DU RECEPTEUR 5-HT2c |
| WO2005087949A1 (en) * | 2004-03-12 | 2005-09-22 | Compugen Ltd. | Systematic mapping of adenosine to inosine editing sites in the human transcriptome |
| GB0420873D0 (en) * | 2004-09-20 | 2004-10-20 | Curidium Ltd | Methods of diagnosis |
| US20100008921A1 (en) * | 2005-06-16 | 2010-01-14 | Evotec Neurosciences Gmbh | Diagnostic and Therapeutic Target Adarb2 Proteins for Neurodegenerative Diseases |
-
2008
- 2008-06-13 ES ES17185202T patent/ES2952748T3/es active Active
- 2008-06-13 CN CN200880019753.XA patent/CN101743322B/zh active Active
- 2008-06-13 JP JP2010511663A patent/JP5661458B2/ja active Active
- 2008-06-13 EP EP08761038.2A patent/EP2162550B1/en not_active Not-in-force
- 2008-06-13 EP EP17185202.3A patent/EP3272881B9/en active Active
- 2008-06-13 ES ES08761038.2T patent/ES2646592T3/es active Active
- 2008-06-13 WO PCT/EP2008/057519 patent/WO2008152146A1/en not_active Ceased
- 2008-06-13 CA CA2690909A patent/CA2690909C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3272881B1 (en) | 2023-06-07 |
| WO2008152146A1 (en) | 2008-12-18 |
| CA2690909C (en) | 2022-01-18 |
| JP2010528672A (ja) | 2010-08-26 |
| CA2690909A1 (en) | 2008-12-18 |
| CN101743322A (zh) | 2010-06-16 |
| ES2646592T3 (es) | 2017-12-14 |
| EP2162550A1 (en) | 2010-03-17 |
| EP2162550B1 (en) | 2017-08-09 |
| EP3272881C0 (en) | 2023-06-07 |
| EP3272881A1 (en) | 2018-01-24 |
| CN101743322B (zh) | 2014-12-24 |
| EP3272881B9 (en) | 2023-10-04 |
| JP5661458B2 (ja) | 2015-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2952748T3 (es) | Muestra de tejido periférico que contiene células que expresan el 5HTR2C y/o las ADAR como marcadores de la alteración del mecanismo de edición del ARNm de 5HTR2C y sus aplicaciones | |
| Higashi et al. | Expression and localization of Parkinson's disease‐associated leucine‐rich repeat kinase 2 in the mouse brain | |
| Stevanin et al. | Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum | |
| Judson et al. | Allelic specificity of Ube3a expression in the mouse brain during postnatal development | |
| Lang et al. | Association of a functional BDNF polymorphism and anxiety-related personality traits | |
| DK2751284T3 (en) | PROCEDURE FOR DIAGNOSTICING A NEURODEGENERATIVE DISEASE | |
| Schiffer et al. | Association of the human kainate receptor GluR7 gene (GRIK3) with recurrent major depressive disorder | |
| Lim et al. | Allelic expression of serotonin transporter (SERT) mRNA in human pons: lack of correlation with the polymorphism SERTLPR | |
| Glavan et al. | Identification of transcriptome alterations in the prefrontal cortex, hippocampus, amygdala and hippocampus of suicide victims | |
| Civatte et al. | Expression of the β chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies | |
| Torres et al. | NTRK2 (TrkB gene) variants and temporal lobe epilepsy: A genetic association study | |
| ES2873926T3 (es) | Método para predecir una respuesta al tratamiento con un antagonista del receptor V1B en un paciente con síntomas depresivos y/o síntomas de ansiedad | |
| Udawela et al. | Isoform specific differences in phospholipase C beta 1 expression in the prefrontal cortex in schizophrenia and suicide | |
| Grottick et al. | Neurotransmission-and cellular stress-related gene expression associated with prepulse inhibition in mice | |
| US20180179594A1 (en) | Multiple system atrophy and the treatment thereof | |
| US10851420B2 (en) | Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects | |
| WO2011093393A1 (ja) | Dravet症候群の発症可能性の判定方法およびその利用 | |
| US20100184058A1 (en) | Peripherical tissue sample containing cells expressing the 5htr2c and/or adars as markers of the alteration of the mechanism of the 5htr2c mrna editing and its applications | |
| ES2529692T3 (es) | Diagnóstico de paraplejias espásticas hereditarias (PEH) por detección de una mutación en el gen o la proteína KIAA1840 | |
| ES2688349T3 (es) | Evaluación del riesgo potencial de la alteración del estado de ánimo y el suicidio inducidos farmacológicamente: utilización de una plataforma específica | |
| ES2310057B1 (es) | Metodo de analisis molecular y tratamiento en demencia de cuerpos de lewy. | |
| KR101741596B1 (ko) | Octn1 프로모터 내 단일염기다형성 및 이의 용도 | |
| US11873531B2 (en) | Editing profiling of PDE8A pre-mRNA: use as specific biomarker of ADARs activities in human tissues to diagnose and to predict and assess therapeutic efficacy and/or efficiency or potential drug side effects | |
| Straniero | UNRAVELING THE MOLECULAR COMPLEXITY OF PARKINSON¿ S DISEASE: FROM GENETIC RISK FACTORS TO MENDELIAN CAUSATIVE GENES | |
| KR20160110600A (ko) | 조기발병하는 상염색체 우성 축삭형 샤르코-마리-투스 신경병에 대한 원인 유전자로서 ｄｇａｔ２ 및 이를 이용한 상기 질병의 진단방법 |